PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8734654

Linear scleroderma in children.

L E Eubanks·E I McBurney·W Galen·R Reed
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Linear scleroderma is a cutaneous disease of unknown etiology. It most often affects children, who develop band-like lesions in an asymmetric distribution. The literature is reviewed as to the diagnosis, pathogenesis, and treatment of linear scleroderma. CASE REPORT: Six new cases of linear scleroderma in children are reported. Their ages ranged from 6 to 17 years, and five were girls. A 17-year-old girl had en coup de sabre. Multiple treatment modalities were used. All laboratory testing was negative. CONCLUSIONS: Linear scleroderma is a clinical diagnosis. The pathogenesis remains unknown. A consistently effective therapy has not been found, although diphenylhydantoin and ticlopidine hydrochloride should be evaluated in clinical trials.

Explore related subjects

Administration, TopicalAdolescentAnti-Infective AgentsAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalAspirinBetamethasoneChildDermatologic AgentsDrug Therapy, CombinationFemaleGlucocorticoidsHumansMaleMethylprednisolonePenicillinsPhenytoinScleroderma, LocalizedTiclopidineVitamin ECase ReportsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L E Eubanks, E I McBurney, W Galen, R Reed. 1996. Linear scleroderma in children.. https://doi.org/10.1111/j.1365-4362.1996.tb03633.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors.

A native opioid peptide, [Met5]-enkephalin, termed opioid growth factor (OGF), serves as a constitutively expressed and autocrine produced inhibitory molecule related to developing, neoplastic, renewing, and healing tissues. The present study was designed to examine the effects of interfering with opioid-receptor interaction during re-epithelialization of the cornea in the rat using both systemic injections and topical applications of the potent opioid antagonist naltrexone (NTX). A 4 mm diameter epithelial defect was made in the center of the rat cornea. NTX injected twice daily or applied as eyedrops four times daily significantly accelerated re-epithelialization compared to controls. Beginning as early as 8 h after wounding, both the systemic and topical NTX treatment groups had defects that were approximately 10% to 67% smaller than control abrasions at the time points examined. Similarly, the rate of healing for the NTX groups was 4.7- and 2.8-fold greater than controls for systemic and topical paradigms, respectively. The incidence of complete re-epithelialization in animals given systemic administration of NTX was markedly accelerated in comparison to control rats; however, differences in incidence of repair between NTX and control groups receiving topical application were not observed. These results show that native opioid peptides function in wound healing, and exert a tonically inhibitory influence at the receptor level on repair of corneal epithelial injuries.

Administration, Topical↗
PubMed1998

Heteromeric gap junction channels in rat hepatocytes in which the expression of connexin26 is induced.

More than one isotype of the gap junction channel-forming protein subunit, known as connexin, are synthesized in most mammalian cells. Using a modified primary cell culture of rat hepatocytes, in which both connexin32 and connexin26 were expressed in a comparable degree, the molecular composition of connexin subtypes in a gap junction channel (i.e., homomeric or heteromeric) was studied. A fluorescent dye Lucifer Yellow-coupling among hepatocytes was blocked in the presence of 20 microM beta-glycyrrhetinic acid, and antagonist for the gap junction channel. Similarly, either one of the antibodies raised against connexin32 or connexin26 completely inhibited dye-coupling activity among hepatocytes. In addition, we studied the dye-coupling properties at different extracellular pHs in two primary rat hepatocytes: one in which connexin26 was induced, and the other which expresses connexin32 as a major gap junction channel protein. The dye-coupling among the connexin26-induced hepatocytes was more sensitive to lowering pHs than among the normal hepatocytes, in which less than 5% of gap junction protein is connexin26. Taken together, data obtained in our study strongly suggest that the connexins (32 & 26) are assembled to form heteromeric, rather than homomeric, gap junction channels in the connexin226-induced rat hepatocytes.

Administration, Topical↗
PubMed1998

Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition.

Hydroquinone is a ubiquitous chemical readily available as monographed in cosmetic and nonprescription forms for skin lightening, and is an important industrial chemical. The in vivo bioavailability for 24-h application in humans was 45.3+/-11.2% of dose from a 2% cream formulation containing [14C]hydroquinone, with the majority of radioactivity excreted in the first 24 h. Timed skin wash and skin tape-stripping sequences showed a rapid and continuous movement of hydroquinone into the stratum corneum of human volunteers. Plasma levels taken both ipsilateral and contralateral to the topical dosing site contained radioactivity at the first 0.5-h sampling time. Peak plasma radioactivity was at 4 h in the 8-h blood sampling period. In vitro percutaneous absorption with fresh viable human skin gave a bioavailability of 43.3% of dose, and flux was calculated at 2.85 microg/cm2/h. In vitro, some of the skin samples were pretreated with the metabolic inhibitor sodium azide, which had no effect on percutaneous absorption. Receptor fluid accumulations and 24-h skin samples were extracted and the extracts subjected to thin-layer chromatography (TLC). Control [14C]hydroquinone extraction and TLC had one radioactivity peak, hydroquinone. Receptor fluid and skin extraction had a second peak with the same Rf as benzoquinone, which was decreased with azide treatment. No other peaks were found. Ethyl acetate extraction of urine from the in vivo study showed all radioactivity to be only water-soluble, free hydroquinone released following glucuronidase treatment. Risk assessment should not only involve the bioavailability of intact topical hydroquinone, but also consider phase I and phase II metabolism in both humans and any animal for which toxicity potential was assessed.

Administration, Topical↗